EICHOR
● Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Condition: Relapsed/Refractory Hematological Malignancies · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL · Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation) · Sponsor: Ascentage Pharma Group Inc.
About this study
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
This description comes directly from the study's public registry record.
Talk to the study team
Yifan Zhai, M.D., Ph.D. · 18998334688 · Yzhai@ascentage.com
Qiwei Chen, M.D. · Qiwei.Chen@ascentage.com
Always discuss trial participation with your own doctor first.
Locations (6)
| START Los Angele | Los Angeles, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Not Yet Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| The University of TX MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07424833